ArticleJournal of computer-aided molecular design2026
Identification of antidiabetic leads using in-silico screening, molecular dynamics simulation, and biological evaluation using cell viability, anti-adipogenesis, glucose uptake, and peroxisome proliferator activated receptor-γ in-vitro assay.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Type II diabetes mellitus is a major endocrine disorder characterized by persistent hyperglycemia, insulin resistance, and dysregulation in glucose uptake by the cells. Peroxisome proliferator-activated receptor-γ (PPARγ) plays a significant role in the regulation of glucose and lipid metabolism as well as in post-diabetic inflammatory response. Therefore, PPARγ activators seem to be the drugs of choice. In the present work, structure-based virtual screening approach was employed to find newer compounds as PPARγ agonist. The ChemDiv library (freely available) of compounds was used for hierarchical virtual screening; the hits obtained were further evaluated based on in silico predicted binding energy and toxicity predictions. The structure-based approach yielded 18 high-affinity, stably binding hits, from which 08 hits (Sn1-Sn8) were predicted to be non-toxic. Further, in vitro exploration of the anti-diabetic as well as PPARγ agonistic potential was carried out on eight (08) ligands obtained from in silico scrutiny, using various in vitro assays. The synthesized quinazolinedione based compound (Sn9) was also evaluated similarly for exploration of its lead-likeness as PPARγ agonistic anti-diabetic candidate. Compounds Sn7 and Sn8 showed adequate glucose uptake by the cells, anti-adipogenicity, and PPARγ binding, while Sn4 and Sn9 showed moderate potential in the same examination. Safety profiles of these compounds on 3T3-L1 and C2C12 cells were also established. The in vitro studies suggested that imidazopyridine (present in Sn4, Sn8) and quinazolinedione (present in Sn7 and Sn9) have much potential against T2DM. Sn8 was found to be the best candidate, and it also demonstrated a stable trajectory and interaction profile in simulated physiological environment. The study confirms the lead-like potential of compound Sn8, and supports the exploration of imidazopyridine and quinazolinedione ring systems for further development of PPARγ agonistic lead compounds in the anti-diabetic arena.
Indexed as
Identifiers
41528586What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.